Unlock instant, AI-driven research and patent intelligence for your innovation.

A composition of bacillus licheniformis and xylooligosaccharide and its application

A technology of Bacillus licheniformis and xylo-oligosaccharide, which can be used in drug combinations, medical preparations containing active ingredients, bacteria, etc., can solve problems such as side effects of myopathy, and achieve the effect of high safety

Active Publication Date: 2021-04-27
SHENYANG NO 1 PHARMA FACTORY DONGBEI PHARMA GRP
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] For hypercholesterolemia, statins are commonly used for treatment, but these drugs may cause side effects of myopathy, the common symptom of which is non-specific muscle or joint pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition of bacillus licheniformis and xylooligosaccharide and its application
  • A composition of bacillus licheniformis and xylooligosaccharide and its application
  • A composition of bacillus licheniformis and xylooligosaccharide and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Effects of Bacillus licheniformis and xylo-oligosaccharides alone or in combination on high-fat diet rats

[0033] 1. Method:

[0034] 1.1 Animal grouping and modeling

[0035]Thirty healthy SD male rats were purchased from the Experimental Animal Center of Dalian Medical University, weighing 400±20g. Bacillus licheniformis BL63516 was obtained from Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd. They were randomly divided into control group (CON), high-fat diet group (HF), xylooligosaccharide intervention group (XOS), Bacillus licheniformis intervention group (BL), xylooligosaccharide plus Bacillus licheniformis combined intervention group (XOS- BL), 6 rats in each group. Except for the normal control group, the other groups were all given a high-fat diet (see Table 1 for the ingredients of the high-fat rat diet), and at the same time were fed with 10 mg / ml propylthiouracil (PTU) every day. At the same time, the rats in the XOS group were fed...

Embodiment 2

[0178] Evaluation of the effects of Bacillus licheniformis and xylo-oligosaccharides alone or in combination on the intestinal mucosal barrier function of antibiotic-induced impaired mice

[0179] 1. Test method

[0180] 1.1 Establishment of animal models

[0181] Fifty healthy and clean male BALB / C male mice, weighing 20±2g, were purchased from the Experimental Animal Center of Dalian Medical University. Randomly divided into normal control group (CON group, n=10), model group (CS group, n=10), xylooligosaccharide intervention group (XOS group, n=10), Bacillus licheniformis intervention group (BL group, n=10), n=10), xylo-oligosaccharide plus Bacillus licheniformis combined intervention group (XOS-BL group, n=10). For the first 8 days, the mice in the CON group were given 0.2ml of normal saline per day, twice a day, and the mice in the other four groups were given 0.2ml of 300mg / ml ceftriaxone sodium, twice a day, and a large amount of antibiotics were taken for a short per...

Embodiment 3

[0192] Regulatory effects of Bacillus licheniformis and xylo-oligosaccharides on dextran sodium sulfate (DSS)-induced colitis in mice

[0193] 1. Method:

[0194] 1.1 Animal grouping and modeling

[0195] Fifty healthy BALB / C female mice, weighing 20±2g, were purchased from the Experimental Animal Center of Dalian Medical University. Randomly divided into normal control group (control group), colitis model group (DSS group), xylo-oligosaccharide intervention group (sugar group), Bacillus licheniformis intervention group (bacteria group), xylo-oligosaccharide plus Bacillus licheniformis combined Intervention group (sugar plus bacteria group), 10 rats in each group. Except for the normal control group, the mice in the other 4 groups were given 3% (m / v) DSS as the only drinking water and drank freely, and the colitis model was established for 7 days. At the same time, from the first day of 3% DSS free drinking, the mice in the sugar group were fed with 0.012g / ml Bacillus liche...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition of bacillus licheniformis and xylo-oligosaccharides and its use relate to the field of compound medicines. The pharmaceutical composition can synergistically reduce low-density lipoprotein cholesterol and / or total cholesterol, and has the characteristics of high safety and the like.

Description

technical field [0001] The invention relates to a pharmaceutical composition of bacillus licheniformis and xylo-oligosaccharide in the field of compound medicine and its application. Background technique [0002] Bacillus licheniformis BL63516 live bacteria capsule is a kind of widely used aerobic probiotic preparation. After oral administration into the intestinal tract, it creates an anaerobic environment in the intestinal cavity by capturing oxygen molecules, and promotes the growth of anaerobic bacteria ( Such as Bifidobacterium, Lactobacillus, etc.), can inhibit the growth of spoilage bacteria and reduce the production of bacterial endotoxins; reduce the pH value of the intestinal tract, and maintain an acidic environment that is conducive to the excretion of ammonia and endotoxins. Chinese patent 92113318.9 reports Bacillus licheniformis strain 63516 and its use in treating diarrhea, which is currently commonly used in the treatment of diarrhea in children and adults. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20
CPCA61K31/702A61K31/715A61K35/742A61P3/06A61K2300/00
Inventor 苏显英袁杰力刘素娜李明周联波刘曼王玉军周娇锐吴楠魏斌于雯彭勃
Owner SHENYANG NO 1 PHARMA FACTORY DONGBEI PHARMA GRP